跳至主要内容
临床试验/CTRI/2025/09/094884
CTRI/2025/09/094884已完成不适用

To evaluate the in vivo safety and efficacy of cosmetic formulation in Conferring skin benefits in healthy human Indian subjects

ITC LIMITED1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2025年9月22日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
ITC LIMITED
入组人数
90
试验地点
1
主要终点
Skin cleansing, Sebum and Acne Control, overall skin parameters

研究概览

简要总结

Brief Summary: The study aims at assessing the safety and skin benefitting efficacy of the investigational products over a 28 day use duration by healthy human Indian adults with periodic assessments pre and post use, 1 day post use, Post 1 week, 2 weeks, 3 weeks and 4 weeks of Use.

Assessments:(a) Non invasive Insturmental measurements for skin hydration,  barrier, Sebum, imaging.

(b) Dermatologists Assessment of product safety, tolerance and skin benefitting efficacy and

(c) Subjects self assessment of product safety, tolerance and skin benefitting efficacy.

研究设计

研究类型
Interventional
分配方式
Na
盲法
Participant and Outcome Assessor Blinded

入排标准

年龄范围
19.00 Year(s) 至 35.00 Year(s)(—)
性别
All

入选标准

  • Subjects with Acne prone skin and uneven skin tone.
  • Subjects with no cuts, abrasions, wounds, injuries, allergies, tattoos, scars, henna or any other developments / artefacts on face and forearms that can impact the measurements.
  • Subjects willing to abide by the study protocol, laid restrictions and consenting to visit the site for periodic assessments on the scheduled dates.

排除标准

  • For Females:Being pregnant or breastfeeding or having stopped to breastfeed in the past three months.
  • Having refused to give his/her assent by not signing the consent form and Informed consent form
  • Taking part in another study liable to interfere with this study
  • Being known diabetic case
  • Known asthma case
  • Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area (except for specific studies on a determined dermatosis)
  • Being known thyroid case
  • Being epileptic.
  • Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes or corticosteroid by any route (the only medication permitted is paracetamol)
  • Known case of hypersensitivity.
  • Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products.
  • Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months.

结局指标

主要结局

Skin cleansing, Sebum and Acne Control, overall skin parameters

时间窗: Pre use, Post 1 use, 1 day post use, Post 7 days, 14 days, 21days and 28 days of use

次要结局

未报告次要终点

研究者

发起方
ITC LIMITED
申办方类型
Other [[fmcg]]
责任方
Principal Investigator
主要研究者

Dr Niharika Salian

MASCOT-SPINCONTROL India Pvt. Ltd.

研究点 (1)

Loading locations...

相似试验